www.bjcancer.com

## Short Communication

Mutation analysis of three genes encoding novel LKB1-interacting proteins, BRG1, STRAD $\alpha$ , and MO25 $\alpha$ , in Peutz–Jeghers syndrome

# P Alhopuro<sup>1</sup>, P Katajisto<sup>2</sup>, R Lehtonen<sup>1</sup>, SK Ylisaukko-oja<sup>1</sup>, L Näätsaari<sup>1</sup>, A Karhu<sup>1</sup>, AM Westerman<sup>3</sup>, JHP Wilson<sup>3</sup>, FWM de Rooij<sup>3</sup>, T Vogel<sup>4</sup>, G Moeslein<sup>5</sup>, IP Tomlinson<sup>6</sup>, LA Aaltonen<sup>1</sup>, TP Mäkelä<sup>2</sup> and V Launonen<sup>\*,1</sup>

<sup>1</sup>Department of Medical Genetics, Biomedicum Helsinki (Haartmaninkatu 8), University of Helsinki, Helsinki FIN-00014, Finland; <sup>2</sup>Molecular Cancer Biology Program, Institute of Biomedicine and Helsinki University Central Hospital, Biomedicum Helsinki, Helsinki, Finland; <sup>3</sup>Laboratory of Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; <sup>4</sup>Unfallchirurgie, Universitätsklinikum, Heinrich Heine Universität, Düsseldorf, Germany; <sup>5</sup>Allgemein- und Viszeralchirurgie, Universitätsklinikum, Heinrich Heine Universität, Düsseldorf, Germany; <sup>6</sup>Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, 44, Lincoln's Inn Fields, London WC2A 3PX, UK

Mutations in *LKB1* lead to Peutz–Jeghers syndrome (PJS). However, only a subset of PJS patients harbours *LKB1* mutations. We performed a mutation analysis of three genes encoding novel LKB1-interacting proteins, *BRG1*, *STRADa*, and *MO25a*, in 28 *LKB1*-negative PJS patients. No disease-causing mutations were detected in the studied genes in PJS patients from different European populations.

British Journal of Cancer (2005) **92,** 1126–1129. doi:10.1038/sj.bjc.6602454 www.bjcancer.com Published online 8 March 2005 © 2005 Cancer Research UK

Keywords: Peutz-Jeghers syndrome; BRG1; STRADa; MO25a; LKB1

Peutz-Jeghers syndrome (PJS) is an autosomal dominantly inherited disorder characterised by mucocutaneous pigmentation, hamartomatous polyps of the gastrointestinal tract, and a predisposition to cancer at a young age (Giardiello *et al*, 1987, 2000; Hemminki, 1999). The majority of cancers in PJS patients occur in the stomach and upper small bowel, whereas the most frequently diagnosed extraintestinal cancers are those of the pancreas, breast, and testis (Giardiello *et al*, 1987).

Inactivating mutations in the serine-threonine kinase *LKB1* (*STK11*) have been causally linked to PJS (Hemminki *et al*, 1997, 1998; Jenne *et al*, 1998). However, 30-82% of PJS patients have no detectable *LKB1* mutations, suggesting locus heterogeneity (Lim *et al*, 2003, and references therein). Moreover, some families have been reported to be clearly unlinked to *LKB1* locus (Mehenni *et al*, 1997; Olschwang *et al*, 1998). Linkage analysis has previously yielded a second locus on chromosome 19q13.4, and recently, a translocation breakpoint was mapped to the same locus, but several genes within this region have subsequently been excluded from having a role in PJS (Mehenni *et al*, 1997; Buchet-Poyau *et al*, 2002; Hearle *et al*, 2004). Thus, current candidates for the second PJS loci are genes known or suggested to interact with *LKB1* either by direct association or functionally.

LKB1 has been suggested to mediate its cellular functions through interactions with a number of proteins including LIP1, BRG1, MO25 $\alpha$  and STRAD $\alpha$  (Marignani *et al*, 2001; Buchet-Poyau *et al*, 2002; Baas *et al*, 2003; Boudeau *et al*, 2003). Of these, BRG1 is

appealing, as Brg1 heterozygous mice form epithelial subcutaneous tumours (Bultman *et al*, 2000). LKB1 has been proposed to associate with and stimulate BRG1, and LKB1 might have a role in BRG1-dependent growth arrest (Marignani *et al*, 2001). Both STRAD $\alpha$  and MO25 $\alpha$  have been identified by two independent methods: by probing AMPKK fractions using antibodies against LKB1, STRAD $\alpha$ , and MO25 $\alpha$ , and by purification of LKB1 binding proteins (Baas *et al*, 2003; Boudeau *et al*, 2003; Brajenovic *et al*, 2004). STRAD $\alpha$  is the first identified LKB1 substrate *in vivo*. Furthermore, both STRAD $\alpha$  and MO25 $\alpha$  have been shown to translocate LKB1 from the nucleus to cytoplasm, and interestingly, previous studies have shown that cytoplasmic localisation is significant for LKB1 growth suppressive function (Tiainen *et al*, 1999, 2002).

Of the LKB1-interacting proteins, only LIP1 (Buchet-Poyau *et al*, 2002) has been analysed as a candidate for a second PJS locus. Here, we have extended this approach by analysing three interesting genes encoding LKB1-interacting proteins: *BRG1*, *STRAD* $\alpha$ , and *MO25\alpha*.

#### MATERIALS AND METHODS

A total of 27 *LKB1* mutation-negative PJS patients from four different European countries (seven from Finland, eight from UK, two from the Netherlands, and 10 from Germany) were included in the study. A diagnosis of PJS was made when the patient presented with two or more PJS polyps, one polyp and typical pigmented lesions, or one polyp and a family history of PJS (Tomlinson and Houlston, 1997). Additionally, one Finnish patient who had been diagnosed with a single PJS polyp at the age of 29 years, with

<sup>\*</sup>Correspondence: Dr V Launonen; E-mail: virpi.launonen@helsinki.fi Received 19 May 2004; revised 1 January 2005; accepted 11 January 2004; published online 8 March 2005

unknown family history, was included in the mutation screening. Sporadic disease was diagnosed in 15 (54%) patients and familial disease in 10 patients (36%). No family history was available from three patients. DNA extraction was performed using standard methods. Healthy controls were obtained from the Finnish Red Cross Blood Transfusion Service.

All 34 coding exons and the flanking intronic sequences of *BRG1* (NM\_003072.1) were amplified in 38 fragments. Denaturing highperformance liquid chromatography (DHPLC) method was used in preliminary mutation screening with automated HPLC instrumentation (Agilent Technologies, Palo Alto, CA, USA), and Helix DNA  $50 \times 3.0 \text{ mm} \times 1/4''$  analytical column (Varian Inc. Palo Alto, CA, USA). Optimal melting temperatures for each amplicon were obtained using an algorithm at the Stanford DHPLC Melt program web page (http://insertion.stanford.edu/melt1.html). The analytical acetonitrile gradient was composed by mixing Helix BufferPak A for DHPLC and 55-75% B (Varian) at flow rate of 0.4 ml min<sup>-1</sup>. All samples displaying aberrant or ambiguous pattern in DHPLC were reanalysed by sequencing with ABI 3730 sequencer (Applied Biosystems, Foster City, CA, USA). Polymerase chain reaction (PCR) primers are available from the authors upon request.

The mutation screening of the 12 coding exons of  $STRAD\alpha$  (BK001542.1), the eight coding exons of  $MO25\alpha$  (NM\_016289.2), and the flanking intronic regions was performed by genomic sequencing using Applied Biosystems 3730 sequencing analyzer. Polymerase chain reaction conditions and primer sequences are available from the authors upon request.

The potential effect of silent polymorphisms, intronic, and UTR changes to splicing were predicted by computational methods using NetGene2 splice site prediction web server (http://genome.cbs.dtu.dk/services/NetGene2/). Silent polymorphisms in exons 5 and 27 of BRG1 were predicted to alter splicing in silico. The polymorphism in exon 5 was predicted to increase the probability of cryptic acceptor splice sites flanking the mutation site, whereas in exon 27, a new cryptic donor splice site was predicted. To study the effect at the RNA level, RNA from cultured lymphoblasts was extracted, and reverse transcriptase-PCR (RT-PCR) reactions and cDNA amplifications were performed using standard protocols. Potential splicing variants were visualised by 2% agarose gel electrophoresis. Furthermore, to detect possible effects of altered splicing to expression, real-time PCR was performed using ABI Prism 5700 sequence detection system (Applied Biosystems) and SYBR Green PCR master mix (Applied Biosystems). cDNA samples from two unaffected individuals were used as controls. Primers used were as follows: 5'-AAGCCCTGGCCTGAAGGA-3' and 5'-TGCGGGGGAATCAGCTTCT-3' for the exon 5 change and 5'-GGCGTCAACCCCGACTT-3' and 5'-TGCGCATGAACAGAT 1127

CAAACTC-3' for the exon 27 change. The reverse primers were designed so that they located in the potentially spliced cDNA segment. *GAPDH* and *TBP* were used as control genes to normalise the reactions.

#### **RESULTS AND DISCUSSION**

To determine whether BRG1, STRAD $\alpha$ , or MO25 $\alpha$  are mutated in LKB1 mutation-negative PJS patients, we performed a mutation screening in a set of 28 patient samples. Mutation analysis of BRG1 was performed by DHPLC. The sensitivity of the method has been shown to vary between 93 and 100%, consistently exceeding 96% (Xiao and Oefner, 2001). In BRG1, two novel silent changes were observed (Table 1). A Pro327Pro (c.980A>C) change in exon 5 and a Pro1297Pro (c.3890C>G) change in exon 27 were both found in 4% (one of 28) of the subjects (allele frequency 2%). The Pro1297Pro variant was also detected in healthy controls (two of 188, allele frequency 0.5%), whereas DHPLC analysis of 267 healthy controls revealed no Pro327Pro changes. Splicing effects of these variants were subsequently tested in silico, and the Pro327Pro change was predicted to alter acceptor splice site of exon 5 and the Pro1297Pro change to create a potentially new donor splicing site. To further discern the effects of these variants to splicing, RT-PCR analysis was performed. However, no alternate transcripts were detected at the RNA level (Figure 1). Furthermore, quantitative real-time PCR was performed to detect possible changes in expression caused by alternative splicing. Means of normalised expressions of BRG1 were 1.5 (s.d. 0.14) and 1.4 (s.d. 0.31) in patient with Pro327Pro and normal controls, respectively. Means of normalised expressions of BRG1 were 1.6 (s.d. 0.28) and 1.4 (s.d. 0.26) in patients with Pro1297Pro and normal controls, respectively. Thus, no decrease in BRG1 expression levels was observed in patients with Pro327Pro and Pro1297Pro mutations when compared to controls.

Five previously reported silent polymorphisms were detected: Ala503Ala, His508His, Asp1351Asp, Asp1528Asp, and Asp1628Asp (Valdman *et al*, 2003; Medina *et al*, 2004, http://www.ensembl.org). Also, a previously described missense polymorphism, Tyr372His, was found in two PJS patients (Medina *et al*, 2004). Additionally, six intronic variants were observed (Table 1). Splicing effect of all intronic variants was subsequently tested *in silico*. One of the variants, IVS17-4C>A, gave little evidence of alternative splicing. The IVS17-4C>A change was found in one PJS patient, but not in 186 healthy controls (Table 1). The effects of this variant could not be studied at the RNA level, because no sample was available.

 Table I
 Summary of BRG1 polymorphisms identified in the study

, , , ,	,			
Variant	Allele frequency (%) in PJS (no. of patients)	Allele frequency (%) in controls	Reference	
Pro327Pro, c.980A > C	2 (1/28)	0 (0/267)	This study	
Tyr372His, c.1114T>C	4 (2/28)		Medina et al (2004)	
Ála503Ala, c.1509A>C	2 (1/27)	_	Medina et al (2004)	
His508His, c.1524T > C	19 (8/27)	_	Ensembl <sup>a</sup>	
Pro1297Pro, c.3890C>G	2 (1/28)	0.5 (2/188)	This study	
Asp1351Asp, c.4333C>T	7 (3/28)		Valdman et al (2003)	
Asp1528Asp, c.4584C>T	4 (2/28)	_	Ensembl <sup>a</sup>	
Asp1628Asp, c.4886T>C	9 (4/28)	_	Ensembl <sup>a</sup>	
IV\$9+29G>A	2 (1/25)	_	This study	
IVS9-37T>C	32 (13/24)	_	This study	
IVSI3+I2C>T	2 (1/28)	_	This study	
IVS17+55G>A	5 (3/28)	_	This study	
IVS17-4C>A	2 (1/28)	0 (0/186)	This study	
IVS32-44C>T	2 (1/28)		This study	
	Variant           Pro327Pro, c.980A>C           Tyr372His, c.1114T>C           Ala503Ala, c.1509A>C           His508His, c.1524T>C           Pro1297Pro, c.3890C>G           Asp1351Asp, c.4333C>T           Asp1528Asp, c.4584C>T           Asp1628Asp, c.4584C>T           VS9-37T>C           IVS17+55G>A           IVS17-4C>A           IVS32-44C>T	VariantAllele frequency (%) in PJS (no. of patients)Pro327Pro, c980A>C2 (1/28)Tyr372His, c.1114T>C4 (2/28)Ala503Ala, c.1509A>C2 (1/27)His508His, c.1524T>C19 (8/27)Pro1297Pro, c.3890C>G2 (1/28)Asp1351Asp, c.4333C>T7 (3/28)Asp1528Asp, c.4584C>T4 (2/28)Asp1628Asp, c.4886T>C9 (4/28)IVS9+29G>A2 (1/25)IVS9-37T>C32 (13/24)IVS17+55G>A5 (3/28)IVS17-4C>A2 (1/28)IVS2-44C>T2 (1/28)	VariantAllele frequency (%) in PJS (no. of patients)Allele frequency (%) in controlsPro327Pro, c.980A>C2 (1/28)0 (0/267)Tyr372His, c.1114T>C4 (2/28)Ala503Ala, c.1509A>C2 (1/27)His508His, c.1524T>C19 (8/27)Pro1297Pro, c.3890C>G2 (1/28)0.5 (2/188)Asp1351Asp, c.4333C>T7 (3/28)Asp1628Asp, c.4584C>T4 (2/28)Asp1628Asp, c.4584C>T9 (4/28)IVS9+29G>A2 (1/25)IVS9-37T>C32 (13/24)IVS17+55G>A5 (3/28)IVS17-4C>A2 (1/28)0 (0/186)IVS32-44C>T2 (1/28)	

---, not tested in this study. <sup>a</sup>http://www.ensembl.org.

1128



**Figure I** Effects of the novel *BRG1* silent polymorphisms to splicing were determined by RT–PCR. No difference in amplicon size was observed between mutated samples (A=Pro327Pro, 478 bp and B=Pro1297Pro, 296 bp) and controls (C1 and C2). ST=size standard (DNA marker).

Table 2	Summary	of STR	ADα	and	MO25α	germline	variants	and	allele
frequencies	detected i	n PJS	patier	nts					

Gene	Location	Variant	Allele frequency (%) (no. of patients with mutation)
STRADα	Exon 2	nt.96T>C	63 (25)
	Intron 2	IVS2+15A>G	2 (1)
	Intron 5	IVS5-30G>C	29 (14)
	Intron 10	IVS10+87	64 (25)
MO25α	Intron 5	IVS5+130T>A	2 (1)
	3'UTR	nt.1419_1420deITT	12 (7)
	3'UTR	nt.1552G>C	5 (3)

In STRAD $\alpha$ , a single-nucleotide polymorphism, a T>C change at position 96 (allele frequency 63%), was observed in the

### REFERENCES

- Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA, Alessi DR, Clevers HC (2003) Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. *EMBO J* 22: 3062–3072
- Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, Prescott AR, Clevers HC, Alessi DR (2003) MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. *EMBO J* 22: 5102-5114
- Brajenovic M, Joberty G, Kuster B, Bouwmeester T, Drewes G (2004) Comprehensive proteomic analysis of human Par protein complexes reveals an interconnected protein network. J Biol Chem 279: 12804– 12811
- Buchet-Poyau K, Mehenni H, Radhakrishna U, Antonarakis SE (2002) Search for the second Peutz-Jeghers syndrome locus: exclusion of the STK13, PRKCG, KLK10, and PSCD2 genes on chromosome 19 and the STK11IP gene on chromosome 2. *Cytogenet Genome Res* **97**: 171-178
- Bultman S, Gebuhr T, Yee D, La Mantia C, Nicholson J, Gilliam A, Randazzo F, Metzger D, Chambon P, Crabtree G, Magnuson T (2000) A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. *Mol Cell* 6: 1287-1295
- Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 119: 1447-1453

noncoding sequence of exon 2. Moreover, three intronic polymorphisms were detected. Sequencing of  $MO25\alpha$  revealed one intronic and two 3'UTR polymorphisms. The detected variants in STRAD $\alpha$  and  $MO25\alpha$  (Table 2) were not predicted to affect splicing *in silico*.

Several previous studies support the hypothesis of locus heterogeneity of PJS. However, linkage data and candidate gene approach have not yielded a second PJS gene (Buchet-Poyau *et al*, 2002). Little has been known about LKB1-interacting proteins until recently. Cellular functions suggested for LKB1 to date include an ability to induce cell cycle arrest through p21, involvement in p53-dependent apoptosis pathway and VEGF signalling, involvement in BRG1-dependent chromatin remodelling, induction of colon epithelial cell polarity, and contribution to cell stress censoring through activation of the AMPK kinases (Tiainen *et al*, 1999; Karuman *et al*, 2001; Marignani *et al*, 2001; Ylikorkala *et al*, 2001; Baas *et al*, 2003; Hawley *et al*, 2003). Furthermore, the recent demonstration that LKB1 acts as an *in vivo* activating kinase for at least 13 other kinases suggests that LKB1 will be involved in several as yet uncharacterised functions (Lizcano *et al*, 2004).

Proteins interacting with LKB1 and enhancing its tumour suppressor function are attractive candidates for the second PJS locus. Here, we analysed three genes encoding LKB1-interacting proteins: *BRG1*, *STRAD* $\alpha$ , and *MO25* $\alpha$ . While our approach is unable to detect some mutation types, such as large deletions, the results suggest that germline mutations in these three genes have no major contribution to PJS. These genes were selected as the best candidates at the initiation of the study. Nevertheless, the recent identification of a number of *in vivo* substrates of LKB1 as well as the identification of MO25 $\beta$  and STRAD $\beta$  provide several novel interesting candidates to be analysed in subsequent studies (Boudeau *et al*, 2003; Lizcano *et al*, 2004).

#### ACKNOWLEDGEMENTS

We thank Mikko Aho, Tomi Kempas, Sini Marttinen, Inga-Lill Svedberg, and Iina Vuoristo for technical assistance. The study was supported by grants from Academy of Finland (76227, 77547). A part of this work was carried out at the Academy of Finland's Center of Excellence in Disease Genetics (44870, Finnish Center of Excellence Program 2000–2005).

- Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV, Krush AJ, Yardley JH, Luk GD (1987) Increased risk of cancer in the Peutz-Jeghers syndrome. *N Engl J Med* **316**: 1511–1514
- Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG (2003) Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J Biol* **2**: 28
- Hearle N, Lucassen A, Wang R, Lim W, Ross F, Wheeler R, Moore I, Shipley J, Houlston R (2004) Mapping of a translocation breakpoint in a Peutz–Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp and *STK11*-negative PJS cases. *Genes Chromosomes Cancer* **41**: 164–169
- Hemminki A (1999) The molecular basis and clinical aspects of Peutz-Jeghers syndrome. *Cell Mol Life Sci* 55: 735-750
- Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* 391: 184-187
- Hemminki A, Tomlinson I, Markie D, Jarvinen H, Sistonen P, Bjorkqvist AM, Knuutila S, Salovaara R, Bodmer W, Shibata D, de la Chapelle A, Aaltonen LA (1997) Localization of a susceptibility locus for Peutz-

**Genetics and Geno** 

Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 15: 87-90

- Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W, Zimmer M (1998) Peutz Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nat Genet* 18: 38-43
- Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R, Brien TP, Bozzuto CD, Ooi D, Cantley LC, Yuan J (2001) The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. *Mol Cell* 7: 1307-1319
- Lim W, Hearle N, Shah B, Murday V, Hodgson SV, Lucassen A, Eccles D, Talbot I, Neale K, Lim AG, O'Donohue J, Donaldson A, Macdonald RC, Young ID, Robinson MH, Lee PW, Stoodley BJ, Tomlinson I, Alderson D, Holbrook AG, Vyas S, Swarbrick ET, Lewis AA, Phillips RK, Houlston RS (2003) Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. *Br J Cancer* 89: 308–313
- Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG, Alessi DR (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. *EMBO J* **23**: 833-843
- Marignani PA, Kanai F, Carpenter CL (2001) LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest. J Biol Chem 276: 32415-32418
- Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M (2004) Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. *Genes Chromosomes Cancer* **41**: 170–177

- Mehenni H, Blouin JL, Radhakrishna U, Bhardwaj SS, Bhardwaj K, Dixit VB, Richards KF, Bermejo-Fenoll A, Leal AS, Raval RC, Antonarakis SE (1997) Peutz Jeghers syndrome: confirmation of linkage to chromosome 19p13.3 and identification of a potential second locus, on 19q13.4. *Am J Hum Genet* **61**: 1327–1334
- Olschwang S, Markie D, Seal S, Neale K, Phillips R, Cottrell S, Ellis I, Hodgson S, Zauber P, Spigelman A, Iwama T, Loff S, McKeown C, Marchese C, Sampson J, Davies S, Talbot I, Wyke J, Thomas G, Bodmer W, Hemminki A, Avizienyte E, de la Chapelle A, Aaltonen L, Tomlinson I (1998) Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet 35: 42-44
- Tiainen M, Vaahtomeri K, Ylikorkala A, Makela TP (2002) Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). *Hum Mol Genet* 11: 1497-1504
- Tiainen M, Ylikorkala A, Makela TP (1999) Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. *Proc Natl Acad Sci USA* **96**: 9248 – 9251
- Tomlinson IP, Houlston RS (1997) Peutz-Jeghers syndrome. J Med Genet 34: 1007-1011
- Valdman A, Nordenskjold A, Fang X, Naito A, Al-Shukri S, Larsson C, Ekman P, Li C (2003) Mutation analysis of the BRG1 gene in prostate cancer clinical samples. *Int J Oncol* 22: 1003–1007
- Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17: 439-474
- Ylikorkala A, Rossi DJ, Korsisaari N, Luukko K, Alitalo K, Henkemeyer M, Makela TP (2001) Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. *Science* **293:** 1323-1326